Detailansicht

Wissensnetz

Person

Florian Heidel (1976-)

Hämatologe

Name	Florian Heidel
Zeit	1976- (Lebensdaten)
Ort	Erlangen (Geburtsort) Hannover (Wirkungsort) Greifswald (Wirkungsort) Jena (Wirkungsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. med. habil. (Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät)
Beruf	Hämatologe (charakteristischer Beruf) Arzt Hochschullehrer
Variante	Florian H. Heidel
Beziehung	Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation (Direktor) (08/2023-) Universitätsmedizin Greifswald (Direktor) (10/2020-08/2023) Klinik für Innere Medizin II (Jena) (Stellvertretender Direktor, Professor) (12/2015-10/2020)
Quelle	ResearchGate: https://www.researchgate.net/profile/Florian-Heidel (Stand: 05.12.2024) https://www.mhh.de/haematologie/standard-titel/direktor-2 (Stand: 05.12.2024) https://www.heidel-lab.com (Stand: 05.12.2024)
Datensatztyp	Person
GND-Nummer	128578157
Datensatz-ID	128578157
Beteiligt an alle anzeigen MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) Genetic vulnerabilities in acute myeloid leukemia Humorale und zelluläre Immunantwort auf eine COVID-19-Impfung bei hämatoonkologischen Patientinnen mit myeloischer oder lymphatischer Neoplasie und bei Patientinnen mit solidenTumoren unter Checkpoint-Inhibitor-Therapie im Vergleich zu Proband*innen ohne Tumorerkrankung Identifizierung von funktionellen Vulnerabilitäten in myeloischen Erkrankungen Mutation patterns and clonal evolution in myeloproliferative neoplasms Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany Pomalidomide combinations are a safe and effective option after daratumumab failure Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis Pomalidomide combinations are a safe and effective option after daratumumab failure Pomalidomide combinations are a safe and effective option after daratumumab failure Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity Therapiestrategien bei myeloproliferativen Neoplasien Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML) Analysis of the functional roles of NADPH oxidase 4 (NOX4) in normal hematopoiesis and myeloid malignancies Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML) Cytoreductive treatment in real life: : a chart review analysis on 1440 patients with polycythemia vera Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Identifizierung neuer molekularer Zielstrukturen für die Behandlung von myeloischen Neoplasien P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia Therapie der chronischen myeloischen Leukämie in einer hämatologischen Schwerpunktpraxis mit Fokus auf Tyrosinkinaseinhibitor-Absetzversuche Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis Forward genetic screening identifies actionable drivers of B-cell lymphomagenesis Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance Pharmakologische und genetische Inaktivierung des Kälteschockproteins YB-1 in der akuten myeloischen Leukämie Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders Autoantikörperformation und Kartierung von immunogenen Epitopen gegen das Kälteschockprotein YB-1 in Tumorpatienten und gesunden Kontrollprobanden Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation Einfluss von Hypoxie und Hypoxie-relevanter Signalwege auf die Entstehung und Progression des malignen Melanoms Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany Leukemogenic potency of the novel FLT3-N676K mutant Leukemic mastopathy Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells Molecular pathogenesis of myeloid neoplasia and therapeutic implications = Molekulare Pathogenese von myeloischen Neoplasien und deren therapeutische Beeinflussbarkeit Entwicklung von Tyrosinkinase‐Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia Die Rolle des INK4A, p-16-Genlocus in der Pathogenese von akuten lymphoblastischen Leukämien im Kindesalter mit Translokation t(4;11)-

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Florian Heidel (1976-)

MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients

Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Genetic vulnerabilities in acute myeloid leukemia

Humorale und zelluläre Immunantwort auf eine COVID-19-Impfung bei hämatoonkologischen Patient*innen mit myeloischer oder lymphatischer Neoplasie und bei Patient*innen mit solidenTumoren unter Checkpoint-Inhibitor-Therapie im Vergleich zu Proband*innen ohne Tumorerkrankung

Identifizierung von funktionellen Vulnerabilitäten in myeloischen Erkrankungen

Mutation patterns and clonal evolution in myeloproliferative neoplasms

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

Pomalidomide combinations are a safe and effective option after daratumumab failure

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis

Pomalidomide combinations are a safe and effective option after daratumumab failure

Pomalidomide combinations are a safe and effective option after daratumumab failure

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity

Therapiestrategien bei myeloproliferativen Neoplasien

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)

Analysis of the functional roles of NADPH oxidase 4 (NOX4) in normal hematopoiesis and myeloid malignancies

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)

Cytoreductive treatment in real life: : a chart review analysis on 1440 patients with polycythemia vera

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Identifizierung neuer molekularer Zielstrukturen für die Behandlung von myeloischen Neoplasien

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

Therapie der chronischen myeloischen Leukämie in einer hämatologischen Schwerpunktpraxis mit Fokus auf Tyrosinkinaseinhibitor-Absetzversuche

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Forward genetic screening identifies actionable drivers of B-cell lymphomagenesis

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance

Pharmakologische und genetische Inaktivierung des Kälteschockproteins YB-1 in der akuten myeloischen Leukämie

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders

Autoantikörperformation und Kartierung von immunogenen Epitopen gegen das Kälteschockprotein YB-1 in Tumorpatienten und gesunden Kontrollprobanden

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation

Einfluss von Hypoxie und Hypoxie-relevanter Signalwege auf die Entstehung und Progression des malignen Melanoms

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN

Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany

Leukemogenic potency of the novel FLT3-N676K mutant

Leukemic mastopathy

Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

Molecular pathogenesis of myeloid neoplasia and therapeutic implications = Molekulare Pathogenese von myeloischen Neoplasien und deren therapeutische Beeinflussbarkeit

Entwicklung von Tyrosinkinase‐Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia

Die Rolle des INK4A, p-16-Genlocus in der Pathogenese von akuten lymphoblastischen Leukämien im Kindesalter mit Translokation t(4;11)-

Humorale und zelluläre Immunantwort auf eine COVID-19-Impfung bei hämatoonkologischen Patientinnen mit myeloischer oder lymphatischer Neoplasie und bei Patientinnen mit solidenTumoren unter Checkpoint-Inhibitor-Therapie im Vergleich zu Proband*innen ohne Tumorerkrankung